Xoraxon Generic. Price Of Xoraxon. Uses, Dosage, Side Effects

How times a day do you take this medicine?Once in a day Twice in a day 3 times in a day 4 times in a day sponsored Uses Dosage Side effects Pregnancy Overdose Actions

• Xoraxon indications
• Uses of Xoraxon in details
• Xoraxon description
• Xoraxon dosage
• Xoraxon interactions
• Xoraxon side effects
• Xoraxon contraindications

What is Xoraxon?

Xoraxon is used to treat bacterial infections in many different parts of the body. Xoraxon is also given before certain types of surgery to prevent infections.

Xoraxon belongs to the class of medicines known as cephalosporin antibiotics. It works by killing bacteria or preventing their growth. However, Xoraxon will not work for colds, flu, or other virus infections.

Xoraxon is available only with your doctor's prescription.

Xoraxon indications

sponsored

Before instituting treatment with B Braun Xoraxon, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of B Braun Xoraxon and other antibacterial drugs, B Braun Xoraxon should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

B Braun Xoraxon is indicated for the treatment of the following infections when caused by susceptible organisms: Lower respiratory tract infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia. coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens.

Skin and skin structure infections caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Viridans group streptococci, Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii*, Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis* or Peptostreptococcus spp.

Urinary tract infections (complicated and uncomplicated) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae.

Pelvic inflammatory disease caused by Neisseria gonorrhoeae. Xoraxon sodium, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added.

Bacterial septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae.

Bone and joint infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter spp.

Intra-abdominal infections caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium spp (Note: Most strains of Clostridium difficile are resistant) or Peptostreptococcus spp.

Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae.

Xoraxon sodium has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis* and Escherichia coli*.

*Efficacy for this organism in this organ system was studied in fewer than 10 infections.

Surgical Prophylaxis: The preoperative administration of a single 1 g dose of B Braun Xoraxon may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (eg, vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients eg, those >70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (eg, during coronary artery bypass surgery). Although Xoraxon sodium has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery.

When administered prior to surgical procedures for which it is indicated, a single 1 g dose of B Braun Xoraxon provides protection from most infections due to susceptible organisms throughout the course of the procedure.

How should I use Xoraxon?

Use Xoraxon as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Xoraxon is usually given as an injection at your doctor's office, hospital, or clinic. If you will be using Xoraxon at home, a health care provider will teach you how to use it. Be sure you understand how to use Xoraxon. Follow the procedures you are taught when you use a dose. Contact your health care provider if you have any questions.
• Xoraxon is light yellow to amber in color. Do not use Xoraxon if it contains particles, is cloudy or discolored, or if the vial or container is cracked or damaged in any way.
• To clear up your infection completely, use Xoraxon for the full course of treatment. Keep using it even if you feel better in a few days.
• Keep this product, as well as syringes and needles, out of the reach of children and pets. Do not reuse needles, syringes, or other materials. Ask your health care provider how to dispose of these materials after use. Follow all local rules for disposal.
• If you miss a dose of Xoraxon, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Xoraxon.

Uses of Xoraxon in details

sponsored

Use: Labeled Indications

Bloodstream infection: Caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae, or Klebsiella pneumoniae.

Bone and joint infections (osteomyelitis and/or discitis, prosthetic joint infection, septic arthritis): Caused by S. aureus, S. pneumoniae, E. coli, Proteus mirabilis, K. pneumoniae, or Enterobacter spp.

Gonococcal infection, uncomplicated (cervical/urethral, rectal, and pharyngeal): Caused by Neisseria gonorrhoeae, including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of N. gonorrhoeae.

Intra-abdominal infection, community-acquired (mild to moderate infection in low-risk patients): Caused by E. coli, K. pneumoniae, Bacteroides fragilis, Clostridium spp. (Note: Most strains of C. difficile are resistant), or Peptostreptococcus spp.

Lower respiratory tract infections (pneumonia, community-acquired): Caused by S. pneumoniae, S. aureus, H. influenzae, Haemophilus parainfluenzae, K. pneumoniae, E. coli, Enterobacter aerogenes, P. mirabilis, or Serratia marcescens.

Meningitis, bacterial: Caused by H. influenzae, Neisseria meningitidis, or S. pneumoniae. Xoraxon has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis and E. coli (efficacy for these 2 organisms in this organ system was studied in fewer than 10 infections).

Otitis media, acute: Caused by S. pneumoniae, H. influenzae (including beta-lactamase-producing strains), or Moraxella catarrhalis (including beta-lactamase-producing strains).

Pelvic inflammatory disease (mild to moderate): Caused by N. gonorrhoeae. Xoraxon, like other cephalosporins, has no activity against Chlamydia trachomatis; therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added.

Skin and soft tissue infections: Caused by S. aureus, S. epidermidis, Streptococcus pyogenes, viridans group streptococci, E. coli, Enterobacter cloacae, Klebsiella oxytoca, K. pneumoniae, P. mirabilis, Morganella morganii (efficacy for this organism in this organ system was studied in fewer than 10 infections), S. marcescens, Acinetobacter calcoaceticus, B. fragilis (efficacy for this organism in this organ system was studied in fewer than 10 infections), or Peptostreptococcus spp.

Surgical prophylaxis, colorectal: To reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated.

Urinary tract infection, complicated (including pyelonephritis): Caused by E. coli, P. mirabilis, Proteus vulgaris, M. morganii, or K. pneumoniae.

Off Label Uses

Actinomycosis, severe or extensive

Data from a limited number of patients suggest Xoraxon may be beneficial for the treatment of severe or extensive actinomycosis.

Xoraxon description

sponsored

B Braun Xoraxon is a sterile, nonpyrogenic, single use, packaged combination of Xoraxon sodium and dextrose injection (diluent) in the Duplex sterile container. The Duplex container is a flexible dual chamber container.

The drug chamber is filled with Xoraxon sodium, a sterile, semisynthetic, broad-spectrum cephalosporin antibiotic for IV administration. Xoraxon sodium is (6R,7R)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-triazin-3-yl)thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 72-(Z)-(O-methyloxime), disodium salt, sesquaterhydrate.

Its chemical formula is C18H16N8Na2O7S3·3.5H2O. It has a calculated molecular weight of 661.6.

Xoraxon sodium is supplied as a dry powder form equivalent to either 1 or 2 g of Xoraxon. It is a white to yellowish-orange crystalline powder which is readily soluble in water, sparingly soluble in methanol and very slightly soluble in ethanol. The pH of a 1% aqueous solution is approximately 6.7. The color of Xoraxon sodium solutions ranges from light yellow to amber, depending on the length of storage and concentration.

Xoraxon sodium contains approximately 83 mg (3.6 mEq) of sodium per gram of Xoraxon activity.

The diluent chamber contains dextrose injection. The concentration of hydrous dextrose in water for injection USP has been adjusted to render the reconstituted drug product iso-osmotic. Dextrose USP has been added to adjust osmolality (approximately 1.87 g and 1.11 g to 1 g and 2 g dosages, respectively). Dextrose injection is sterile, nonpyrogenic, and contains no bacteriostatic or antimicrobial agents.

The molecular weight of hydrous dextrose USP is 198.17.

After removing the peelable foil strip, activating the seals, and thoroughly mixing, the reconstituted drug product is intended for single IV use. When reconstituted, the approximate osmolality for the reconstituted solution for B Braun Xoraxon is 290 mOsmol/kg.

The Duplex container is latex-free, PVC-free, and DEHP-free.

The Duplex dual chamber container is made from a specially formulated material. The product (diluent and drug) contact layer is a mixture of thermoplastic rubber and a polypropylene ethylene copolymer that contains no plasticizers. The safety of the container system is supported by USP biological evaluation procedures.

Xoraxon dosage

sponsored

Intended for IV administration only.

B Braun Xoraxon and calcium-containing solutions, including continuous calcium-containing infusions eg, parenteral nutrition, should not be mixed or co-administered to any patient irrespective of age, even via different infusion lines at different sites.

Treatment of Skin and Skin Structure Infections: Recommended Total Daily Dose: 50-75 mg/kg given once a day (or in equally divided doses twice a day). The total daily dose should not exceed 2 g.

Treatment of Serious Miscellaneous Infections Other than Meningitis: Recommended Total Daily Dose: 50-75 mg/kg, given in divided doses every 12 hrs. The total daily dose should not exceed 2 g.

Treatment of Meningitis: Recommended Initial Therapeutic Dose: 100 mg/kg (not to exceed 4 g). Thereafter, a total daily dose of 100 mg/kg/day (not to exceed 4 g daily) is recommended. The daily dose may be administered once a day (or in equally divided doses every 12 hrs). The usual duration of therapy is 7-14 days.

Adults: Usual Daily Dose: 1-2 g given once a day (or in equally divided doses twice a day) depending on the type and severity of infection. The total daily dose should not exceed 4 g.

If Chlamydia trachomatis is a suspected pathogen, appropriate antichlamydial coverage should be added, because Xoraxon sodium has no activity against this organism.

For preoperative use (surgical prophylaxis), a single dose of 1 g administered IV ½-2 hrs before surgery is recommended.

Generally, B Braun Xoraxon therapy should be continued for at least 2 days after the signs and symptoms of infection have disappeared. The usual duration of therapy is 4-14 days; in complicated infections, longer therapy may be required.

When treating infections caused by Streptococcus pyogenes, therapy should be continued for at least 10 days.

Children: B Braun Xoraxon in the Duplex container is designed to deliver a 1 or 2 g dose of Xoraxon. To prevent unintentional overdose, B Braun Xoraxon should not be used in pediatric patients who require less than the full adult dose of Xoraxon.

Neonates: Hyperbilirubinemic neonates, especially prematures, should not be treated with B Braun Xoraxon.

Hepatic and Renal Impairment: No dosage adjustment is necessary for patients with impairment of renal or hepatic function; however, blood levels should be monitored in patients with severe renal impairment (eg, dialysis patients) and in patients with both renal and hepatic dysfunctions.

Administration: Directions for Use: B Braun Xoraxon should be administered IV by infusion over a period of 30 min.

Vancomycin, amsacrine, aminoglycosides and fluconazole are physically incompatible with Xoraxon in admixtures. When any of these drugs are to be administered concomitantly with Xoraxon by intermittent IV infusion, it is recommended that they be given sequentially, with thorough flushing of the IV lines (with one of the compatible fluids) between the administrations.

B Braun Xoraxon should not be physically mixed with or piggybacked into solutions containing other antimicrobial drugs due to possible incompatibility.

After the indicated stability time periods, unused portions of solutions should be discarded.

Xoraxon interactions

See also:What other drugs will affect Xoraxon?

No impairment of renal function after simultaneous administration of Xoraxon with diuretics.

No interference with the action or increase in nephrotoxicity of aminoglycosides during simultaneous administration with Xoraxon. The Xoraxon molecule does not contain the N-methylthio-tetrazole substituent which has been associated with a disulfiram-like effect when alcohol is taken during therapy with certain cephalosporins.

In vitro, chloramphenicol has been shown to be antagonistic with respect to Xoraxon and other cephalosporins.

Caution is advised if concurrent administration of Xoraxon with chloramphenicol is proposed.

In patients treated with Xoraxon, the Coombs' test may rarely become false-positive. Xoraxon eg, other antibiotics, may result in false-positive test for galactosemia. Likewise, non-enzymatic methods for glucose determination in urine may give false-positive results. For this reason, urine glucose determination during therapy with Xoraxon should be done enzymatically.

Xoraxon may adversely affect the efficacy of oral hormonal contraceptives. Consequently, it is advisable to use supplementary (nonhormonal) contraceptive measures during treatment and in the month following treatment.

Incompatibilities: Solutions containing Xoraxon should not be mixed with or added to solutions containing other agents. In particular, Xoraxon is not compatible with calcium-containing solutions eg, Hartmann's solution and Ringer's solution. Xoraxon is not compatible with amsacrine, vancomycin, fluconazole, aminoglycosides and labetalol.

Xoraxon side effects

See also:What are the possible side effects of Xoraxon?

Post-Marketing: During the use of Xoraxon, the following side effects, which were reversible either spontaneously or after withdrawal of the drug, have been observed: Systemic Side Effects: Gastrointestinal complaints (about 2% of the cases): loose stools or diarrhea, nausea, vomiting, stomatitis and glossitis.

Hematological changes (about 2%): eosinophilia, leukopenia, granulocytopenia, hemolytic anemia, thrombocytopenia. Isolated cases of agranulocytosis (<500/mm3) have been reported, most of them after 10 days of treatment and following total doses of 20 g or more.

Skin reactions (about 1%): exanthema, allergic dermatitis, pruritus, urticaria, edema. Isolated cases of severe cutaneous adverse reactions (erythema multiforme, Stevens Johnson syndrome or Lyell's Syndrome/toxic epidermal necrolysis) have been reported.

Other, Rare Side Effects: Headache and dizziness, symptomatic precipitation of Xoraxon calcium salt in the gallbladder, increase in liver enzymes, oliguria, increase in serum creatinine, genital mycosis, fever, shivering and anaphylactic or anaphylactoid reactions.

Interaction with Calcium: Two in vitro studies, one using adult plasma and the other neonatal plasma from umbilical cord blood have been carried out to assess interaction of Xoraxon and calcium. Xoraxon concentrations up to 1 mM (in excess of concentrations achieved in vivo following administration of 2 grams Xoraxon infused over 30 minutes) were used in combination with calcium concentrations up to 12 mM (48 mg/dL). Recovery of Xoraxon from plasma was reduced with calcium concentrations of 6 mM (24 mg/dL) or higher in adult plasma or 4 mM (16 mg/dL) or higher in neonatal plasma. This may be reflective of Xoraxon-calcium precipitation.

A small number of cases of fatal outcomes in which a crystalline material was observed in the lungs and kidneys at autopsy have been reported in neonates receiving Xoraxon and calcium containing fluids. In some of these cases, the same intravenous infusion line was used for both Xoraxon and calcium-containing fluids and in some a precipitate was observed in the intravenous infusion line. At least one fatality has been reported in a neonate in whom Xoraxon and calcium-containing fluids were administered at different autopsy in this neonate. There have been no similar reports in patients other than neonates.

Pseudomembranous enterocolitis and coagulation disorders have been reported as very rare side effects.

Very rare cases of renal precipitation have been reported, mostly in children older than 3 years and who have been treated with either high daily doses (e.g. ≥80 mg/kg/day) or total doses exceeding 10 grams and presenting other risk factors (e.g. fluid restrictions, confinement to bed, etc.). This event may be symptomatic or asymptomatic, may lead to renal insufficiency, and is reversible upon discontinuation of Xoraxon.

Local Side Effects: In rare cases, phlebitis reactions occurred after i.v. administration. These may be minimized by slow (2-4 minutes) injection.

Intramuscular injection without lidocaine solution is painful.

Laboratory Abnormalities: Influence on Diagnostic Tests: In patients treated with Xoraxon the Coombs' test may rarely become false-positive.

Xoraxon, like other antibiotics, may result in false-positive tests for galactosemia.

Likewise, nonenzymatic methods for the glucose determination in urine may give false positive results. For this reason, urine-glucose determination during therapy with Xoraxon should be done enzymatically.

Xoraxon contraindications

See also:What is the most important information I should know about Xoraxon?

Hypersensitivity

Xoraxon is contraindicated in patients with known hypersensitivity to Xoraxon, any of its excipients or to any other cephalosporin. Patients with previous hypersensitivity reactions to penicillin and other beta lactam antibacterial agents may be at greater risk of hypersensitivity to Xoraxon.

Neonates

Premature Neonates

Xoraxon is contraindicated in premature neonates up to a postmenstrual age of 41 weeks (gestational age + chronological age).

Hyperbilirubinemic Neonates

Hyperbilirubinemic neonates should not be treated with Xoraxon. Xoraxon can displace bilirubin from its binding to serum albumin, leading to a risk of bilirubin encephalopathy in these patients.

Neonates Requiring Calcium Containing IV Solutions

Xoraxon is contraindicated in neonates ( ≤ 28 days) if they require (or are expected to require) treatment with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition because of the risk of precipitation of Xoraxon-calcium.

Cases of fatal outcomes in which a crystalline material was observed in the lungs and kidneys at autopsy have been reported in neonates receiving Xoraxon and calcium-containing fluids.

In some of these cases, the same intravenous infusion line was used for both Xoraxon and calcium-containing fluids and in some a precipitate was observed in the intravenous infusion line. There have been no similar reports in patients other than neonates.

Lidocaine

Intravenous administration of Xoraxon solutions containing lidocaine is contraindicated. When lidocaine solution is used as a solvent with Xoraxon for intramuscular injection, exclude all contraindications to lidocaine. Refer to the prescribing information of lidocaine.

Active ingredient matches for Xoraxon:

Ceftriaxone in Egypt.

List of Xoraxon substitutes (brand and generic names)	Sort by popularity
Unit description / dosage (Manufacturer)	Price, USD
Xonline
Xonline 1000mg Injection (Shrinivas Gujarat Laboratories Pvt Ltd)	$ 0.75
XOY (India)
0.5 g x 1's (D.R. Johns Labs)	$ 0.70
1 g x 1's (D.R. Johns Labs)	$ 1.14
Xoy 0.5g INJ / 1 (D.R. Johns Labs)	$ 0.70
Xoy 1g INJ / 1 (D.R. Johns Labs)	$ 1.14
Xoy 1000 mg Injection (D.R. Johns Labs)	$ 1.14
Xoy 500 mg Injection (D.R. Johns Labs)	$ 0.70
XOY 500MG INJECTION 1 vial / 1 GM injection each (D.R. Johns Labs)	$ 1.08
Xoy 0.5g INJ / 1 (D.R. Johns Labs)	$ 0.70
Xoy 1g INJ / 1 (D.R. Johns Labs)	$ 1.14
Xoy 500mg Injection (D.R. Johns Labs)	$ 1.08
Xplocef (India)
Xplocef Vancomycin 0.5 g, Ceftriaxone1 g. VIAL / 10ml (Elder Pharmaceuticals Pvt Ltd)	$ 4.66
10ml (Elder Pharmaceuticals Pvt Ltd)	$ 4.66
Xplocef 2000+1000 Injection (Elder Pharmaceuticals Pvt Ltd)	$ 8.43
Xplocef 1000+500 Injection (Elder Pharmaceuticals Pvt Ltd)	$ 4.66
XPLOCEF 1000MG/500MG INJECTION 1 vial / 10 ML injection each (Elder Pharmaceuticals Pvt Ltd)	$ 5.12
XPLOCEF 1000MG/500MG INJECTION 1 vial / 1 injection each (Elder Pharmaceuticals Pvt Ltd)	$ 4.66
XPLOCEF 2000MG/1000MG INJECTION 1 vial / 20 ML injection each (Elder Pharmaceuticals Pvt Ltd)	$ 8.64
XPLOCEF INJECTION 1 vial / 1 injection each (Elder Pharmaceuticals Pvt Ltd)	$ 8.64
XPLOCEF INJECTION 1 vial / 10 ML injection each (Elder Pharmaceuticals Pvt Ltd)	$ 8.43
Xplocef 2000 mg/1000 mg Injection (Elder Pharmaceuticals Pvt Ltd)	$ 0.43
Xplocef Injection (Elder Pharmaceuticals Pvt Ltd)	$ 8.64
XT Zone
XT Zone 1000+125 Injection (Sozin Flora Pharma)	$ 1.59
Xtenda (Philippines)
Xtenda / vial + amp 10 mL solvent 1 g x 1's (Samchundang Pharm)	$ 18.66
Z-One (India)
Z-One 1g VIAL / 1 (Nordic)
Z-One 250mg VIAL / 1 (Nordic)
Z-One 500mg VIAL / 1 (Nordic)
1 g x 1's (Nordic)
250 mg x 1's (Nordic)
500 mg x 1's (Nordic)
Zax (India)
Zax 0.5g INJ / 1 (Stellar Bio Labs)	$ 0.59
Zax 1g INJ / 1 (Stellar Bio Labs)	$ 0.87
Zax 250mg INJ / 1 (Stellar Bio Labs)	$ 0.36
0.5 g x 1's (Stellar Bio Labs)	$ 0.59
1 g x 1's (Stellar Bio Labs)	$ 0.87
250 mg x 1's (Stellar Bio Labs)	$ 0.36
Zax 500 mg Injection (Stellar Bio Labs)	$ 0.59
Zax 1000 mg Injection (Stellar Bio Labs)	$ 0.87
Zax 250 mg Injection (Stellar Bio Labs)	$ 0.36
Zax T
Zax T 1000+125 Injection (Stellar Bio Labs)	$ 2.02
Zcef
Zcef 1000 mg Injection (Smilax Pharmaceuticals)	$ 0.90
Zcef 250 mg Injection (Smilax Pharmaceuticals)	$ 0.27
Zefaxone (Thailand)
Zefaxone 1 g x 1's (M & h)
See 4644 substitutes for Xoraxon

References

1. DailyMed. "CEFTRIAXONE SODIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
2. PubChem. "ceftriaxone". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
3. DrugBank. "ceftriaxone". http://www.drugbank.ca/drugs/DB01212 (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Xoraxon are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Xoraxon. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

1 consumer reported useful

Was the Xoraxon drug useful in terms of decreasing the symptom or the disease?According to the reports released by ndrugs.com website users, the below mentioned percentages of users say the drug is useful / not useful to them in decreasing their symptoms/disease. The usefulness of the drug depends on many factors, like severity of the disease, perception of symptom, or disease by the patient, brand name used [matters only to a certain extent], other associated conditions of the patient. If the drug is not effective or useful in your case, you need to meet the doctor to get re-evaluated about your symptoms/disease, and he will prescribe an alternative drug.

Users		%
Useful	1	100.0%

Report useful »

Consumer reported price estimates

No survey data has been collected yet Report price estimates »

Consumer reported time for results

No survey data has been collected yet Report time for results »

2 consumers reported age

Users		%
16-29	1	50.0%
< 1	1	50.0%

Report age »

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name: Email: Spam protection: < Type 16 here

Information checked by Dr. Sachin Kumar, MD Pharmacology